this work references cited by second hopReferences
- 2009Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement83,813 cited
- 2003Measuring inconsistency in meta-analyses63,086 cited
- 2009Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.44,857 cited
- 1961An Inventory for Measuring Depression38,018 cited
- 2009Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement37,549 cited
- 2011The Cochrane Collaboration's tool for assessing risk of bias in randomised trials33,776 cited
- 2015Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement26,189 cited
- 2009Introduction to Meta‐Analysis14,215 cited
- 2021Introduction to Meta‐Analysis9,785 cited
- 2016Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial2,196 cited
- 2011Measures of anxiety: State‐Trait Anxiety Inventory (STAI), Beck Anxiety Inventory (BAI), and Hospital Anxiety and Depression Scale‐Anxiety (HADS‐A)1,792 cited
- 2016Psychedelics1,757 cited
- 2016Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial1,696 cited
- 2016Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study
Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work